Laura Cipriani

4PUBLICATIONS
90CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Jul 09, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.

Stefano Scalera, Biagio Ricciuti, Daniele Marinelli

Pageof 1